Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Down 10.3% in December

Iterum Therapeutics plc (NASDAQ:ITRM) saw a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 2,260,000 shares, a drop of 10.3% from the November 30th total of 2,520,000 shares. Approximately 8.5% of the company’s stock are short sold. Based on an average daily trading volume, of 2,800,000 shares, the days-to-cover ratio is presently 0.8 days.

Iterum Therapeutics Price Performance

Shares of Iterum Therapeutics stock opened at $1.77 on Wednesday. Iterum Therapeutics has a 1 year low of $0.81 and a 1 year high of $3.02. The stock has a market cap of $48.70 million, a PE ratio of -0.89 and a beta of 2.40. The firm has a fifty day moving average price of $1.76 and a 200 day moving average price of $1.37.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Iterum Therapeutics in a research note on Tuesday, September 10th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Iterum Therapeutics stock. XTX Topco Ltd bought a new stake in shares of Iterum Therapeutics plc (NASDAQ:ITRM) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 33,040 shares of the company’s stock, valued at approximately $36,000. XTX Topco Ltd owned 0.15% of Iterum Therapeutics as of its most recent SEC filing. 9.21% of the stock is owned by institutional investors and hedge funds.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.